Arcturus Therapeutics Expands Operations Campus In San Diego, California
Founded in 2013, Arcturus Therapeutics is focused on RNA medicines for the treatment of rare diseases. Arcturus has developed a novel, potent and safe RNA Therapeutics platform called LUNAR, a proprietary lipid-enabled delivery system for RNA medicines including small interfering RNA, messenger RNA, antisense, and microRNA oligotherapeutics. The company owns Unlocked Nucleic Acid chemistry technology and patent portfolio enabling the targeting of any gene in the human genome.
"The Arcturus story began at the cutting edge Johnson and Johnson Innovation Center here in San Diego. Today, we are 'graduating' from the incubator space and moving into top-tier facilities that will enable us to execute our vision of bringing transformational life-saving RNA medicines to patients," said Joseph E. Payne, President/CEO of Arcturus Therapeutics, Inc. "We are expanding our work force and hiring key individuals to help us develop premier RNA medicines, such as our lead rare disease drug candidate, LUNAR-101, for treatment of transthyretin-mediated amyloidosis."
"San Diego is a city of innovation. Arcturus Therapeutics is an excellent example of the region's entrepreneurial spirit. Outstanding high-growth biotechnology companies like Arcturus are making us a global leader in technological breakthroughs while also providing high quality jobs for San Diegans here at home," said San Diego Mayor Kevin Faulconer.
Biogen Establishes Research Triangle Park, North Carolina, Gene Therapy Production Campus
Trends in Office and Industrial Parks
34th Annual Corporate Survey & the 16th Annual Consultants Survey
“Made in America” Executive Order to Affect International Companies and FDI
2020 Gold & Silver Shovel Awards Recognize State and Local Economic Development Efforts
Another Look at Rural Economies
Pandemic Fuels Data Center Growth